Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Striking a balance in an antibody network: A roadmap for HIV-1 vaccines.

Charles TP, Derdeyn CA.

J Clin Invest. 2019 Oct 7. pii: 132535. doi: 10.1172/JCI132535. [Epub ahead of print]

2.

Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.

Styles TM, Gangadhara S, Reddy PBJ, Hicks S, LaBranche CC, Montefiori DC, Derdeyn CA, Kozlowski PA, Velu V, Amara RR.

J Virol. 2019 Sep 30;93(20). pii: e00934-19. doi: 10.1128/JVI.00934-19. Print 2019 Oct 15.

PMID:
31341049
3.

Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.

Petitdemange C, Kasturi SP, Kozlowski PA, Nabi R, Quarnstrom CF, Reddy PBJ, Derdeyn CA, Spicer LM, Patel P, Legere T, Kovalenkov YO, Labranche CC, Villinger F, Tomai M, Vasilakos J, Haynes B, Kang CY, Gibbs JS, Yewdell JW, Barouch D, Wrammert J, Montefiori D, Hunter E, Amara RR, Masopust D, Pulendran B.

JCI Insight. 2019 Feb 21;4(4). pii: 126047. doi: 10.1172/jci.insight.126047. eCollection 2019 Feb 21.

4.

VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.

Smith SA, Burton SL, Kilembe W, Lakhi S, Karita E, Price M, Allen S, Derdeyn CA.

Front Immunol. 2019 Jan 15;9:3163. doi: 10.3389/fimmu.2018.03163. eCollection 2018.

5.

Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.

Burton S, Spicer LM, Charles TP, Gangadhara S, Reddy PBJ, Styles TM, Velu V, Kasturi SP, Legere T, Hunter E, Pulendran B, Amara R, Hraber P, Derdeyn CA.

J Virol. 2019 Mar 21;93(7). pii: e01846-18. doi: 10.1128/JVI.01846-18. Print 2019 Apr 1.

6.

HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights.

Shacklett BL, Derdeyn CA, Folayan MO, Landovitz RJ, Anthony C, Behrens AJ, Hope TJ, Landais E, Leal L, Marrazzo JM, Morris L, Mugo N, Ngure K, Noseda V, Ranasinghe S, Tully DC, Voronin Y, Warren M, Wibmer CK, Xie IY, Scarlatti G, Thyagarajan B.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):749-759. doi: 10.1089/AID.2017.0125. Epub 2017 Jul 26.

7.

New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.

Smith SA, Derdeyn CA.

J Virol. 2017 Apr 13;91(9). pii: e00149-17. doi: 10.1128/JVI.00149-17. Print 2017 May 1.

8.

Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.

Kasturi SP, Kozlowski PA, Nakaya HI, Burger MC, Russo P, Pham M, Kovalenkov Y, Silveira ELV, Havenar-Daughton C, Burton SL, Kilgore KM, Johnson MJ, Nabi R, Legere T, Sher ZJ, Chen X, Amara RR, Hunter E, Bosinger SE, Spearman P, Crotty S, Villinger F, Derdeyn CA, Wrammert J, Pulendran B.

J Virol. 2017 Jan 31;91(4). pii: e01844-16. doi: 10.1128/JVI.01844-16. Print 2017 Feb 15.

9.

Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.

Smith SA, Burton SL, Kilembe W, Lakhi S, Karita E, Price M, Allen S, Hunter E, Derdeyn CA.

PLoS Pathog. 2016 Nov 16;12(11):e1005989. doi: 10.1371/journal.ppat.1005989. eCollection 2016 Nov.

10.

Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.

Tian J, López CA, Derdeyn CA, Jones MS, Pinter A, Korber B, Gnanakaran S.

PLoS Comput Biol. 2016 Oct 7;12(10):e1005094. doi: 10.1371/journal.pcbi.1005094. eCollection 2016 Oct.

11.

CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy.

Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, Lawson BO, Nega M, Easley K, Schmitz JE, Bosinger SE, Paiardini M, Chahroudi A, Vanderford TH, Estes JD, Lifson JD, Derdeyn CA, Silvestri G.

Immunity. 2016 Sep 20;45(3):656-668. doi: 10.1016/j.immuni.2016.08.018.

12.

Harnessing the protective potential of HIV-1 neutralizing antibodies.

Smith SA, Derdeyn CA.

F1000Res. 2016 Jan 5;5. pii: F1000 Faculty Rev-20. doi: 10.12688/f1000research.7254.1. eCollection 2016. Review.

13.

Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques.

Smith SA, Kilgore KM, Kasturi SP, Pulendran B, Hunter E, Amara RR, Derdeyn CA.

J Virol. 2015 Dec 16;90(4):1880-7. doi: 10.1128/JVI.02711-15. Print 2016 Feb 15.

14.

A pathway to HIV-1 neutralization breadth.

Smith SA, Derdeyn CA.

Nat Med. 2015 Nov;21(11):1246-7. doi: 10.1038/nm.3989. No abstract available.

15.

Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.

Gu L, Krendelchtchikova V, Krendelchtchikov A, Farrow AL, Derdeyn CA, Matthews QL.

Virology. 2016 Jan;487:75-84. doi: 10.1016/j.virol.2015.10.010. Epub 2015 Oct 23.

16.

Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.

Burton SL, Kilgore KM, Smith SA, Reddy S, Hunter E, Robinson HL, Silvestri G, Amara RR, Derdeyn CA.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10780-5. doi: 10.1073/pnas.1509731112. Epub 2015 Aug 10.

17.

Dualtropic CXCR6/CCR5 Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabey Primary Lymphocytes: Distinct Coreceptor Use in Natural versus Pathogenic Hosts of SIV.

Elliott ST, Wetzel KS, Francella N, Bryan S, Romero DC, Riddick NE, Shaheen F, Vanderford T, Derdeyn CA, Silvestri G, Paiardini M, Collman RG.

J Virol. 2015 Sep;89(18):9252-61. doi: 10.1128/JVI.01236-15. Epub 2015 Jun 24.

18.

Infection of ectocervical tissue and universal targeting of T-cells mediated by primary non-macrophage-tropic and highly macrophage-tropic HIV-1 R5 envelopes.

Peters PJ, Gonzalez-Perez MP, Musich T, Moore Simas TA, Lin R, Morse AN, Shattock RJ, Derdeyn CA, Clapham PR.

Retrovirology. 2015 Jun 9;12:48. doi: 10.1186/s12977-015-0176-2.

19.

Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA.

J Virol. 2015 Aug;89(16):8130-51. doi: 10.1128/JVI.01221-14. Epub 2015 May 27.

20.

HIV-1 non-macrophage-tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4+ T-cells than envelopes highly adapted for macrophages.

Musich T, O'Connell O, Gonzalez-Perez MP, Derdeyn CA, Peters PJ, Clapham PR.

Retrovirology. 2015 Mar 14;12:25. doi: 10.1186/s12977-015-0141-0.

21.

Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.

Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, Rong R, Claiborne DT, Prince JL, Tang J, Ribeiro RM, Cormier E, Hahn BH, Perelson AS, Shaw GM, Karita E, Gilmour J, Goepfert P, Derdeyn CA, Allen SA, Borrow P, Hunter E.

PLoS Pathog. 2015 Jan 8;11(1):e1004565. doi: 10.1371/journal.ppat.1004565. eCollection 2015 Jan.

22.

CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells.

Micci L, Alvarez X, Iriele RI, Ortiz AM, Ryan ES, McGary CS, Deleage C, McAtee BB, He T, Apetrei C, Easley K, Pahwa S, Collman RG, Derdeyn CA, Davenport MP, Estes JD, Silvestri G, Lackner AA, Paiardini M.

PLoS Pathog. 2014 Oct 30;10(10):e1004467. doi: 10.1371/journal.ppat.1004467. eCollection 2014 Oct.

23.

Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.

Li Q, Zeng M, Duan L, Voss JE, Smith AJ, Pambuccian S, Shang L, Wietgrefe S, Southern PJ, Reilly CS, Skinner PJ, Zupancic ML, Carlis JV, Piatak M Jr, Waterman D, Reeves RK, Masek-Hammerman K, Derdeyn CA, Alpert MD, Evans DT, Kohler H, Müller S, Robinson J, Lifson JD, Burton DR, Johnson RP, Haase AT.

J Immunol. 2014 Sep 15;193(6):3113-25. doi: 10.4049/jimmunol.1400820. Epub 2014 Aug 18.

24.

Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection.

Basu D, Xiao P, Ende Z, Bere A, Britt WJ, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E.

Virology. 2014 Aug;462-463:295-8. doi: 10.1016/j.virol.2014.06.016. Epub 2014 Jul 5.

25.

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.

Derdeyn CA, Moore PL, Morris L.

Curr Opin HIV AIDS. 2014 May;9(3):210-6. doi: 10.1097/COH.0000000000000057. Review.

26.

Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques.

Chahroudi A, Cartwright E, Lee ST, Mavigner M, Carnathan DG, Lawson B, Carnathan PM, Hashempoor T, Murphy MK, Meeker T, Ehnert S, Souder C, Else JG, Cohen J, Collman RG, Vanderford TH, Permar SR, Derdeyn CA, Villinger F, Silvestri G.

PLoS Pathog. 2014 Mar 6;10(3):e1003958. doi: 10.1371/journal.ppat.1003958. eCollection 2014 Mar.

27.

Enhanced fusion and virion incorporation for HIV-1 subtype C envelope glycoproteins with compact V1/V2 domains.

Cavrois M, Neidleman J, Santiago ML, Derdeyn CA, Hunter E, Greene WC.

J Virol. 2014 Feb;88(4):2083-94. doi: 10.1128/JVI.02308-13. Epub 2013 Dec 11.

28.

Decreased plasticity of coreceptor use by CD4-independent SIV Envs that emerge in vivo.

Francella N, Elliott ST, Yi Y, Gwyn SE, Ortiz AM, Li B, Silvestri G, Paiardini M, Derdeyn CA, Collman RG.

Retrovirology. 2013 Nov 12;10:133. doi: 10.1186/1742-4690-10-133.

29.

CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.

Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG.

J Virol. 2013 Sep;87(17):9719-32. doi: 10.1128/JVI.01254-13. Epub 2013 Jul 3.

30.

A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein.

Sethi A, Tian J, Derdeyn CA, Korber B, Gnanakaran S.

PLoS Comput Biol. 2013;9(5):e1003046. doi: 10.1371/journal.pcbi.1003046. Epub 2013 May 16.

31.

Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA.

PLoS Pathog. 2013 Feb;9(2):e1003173. doi: 10.1371/journal.ppat.1003173. Epub 2013 Feb 28.

32.

Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis.

Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, Prentice HA, Yue L, Vishwanathan SA, Kilembe W, Goepfert P, Price MA, Gilmour J, Mulenga J, Farmer P, Derdeyn CA, Tang J, Heckerman D, Kaslow RA, Allen SA, Hunter E.

PLoS Pathog. 2012;8(11):e1003041. doi: 10.1371/journal.ppat.1003041. Epub 2012 Nov 29.

33.

Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.

Archary D, Rong R, Gordon ML, Boliar S, Madiga M, Gray ES, Dugast AS, Hermanus T, Goulder PJ, Coovadia HM, Werner L, Morris L, Alter G, Derdeyn CA, Ndung'u T.

Virology. 2012 Nov 25;433(2):410-20. doi: 10.1016/j.virol.2012.08.033. Epub 2012 Sep 18.

34.

HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection.

Basu D, Kraft CS, Murphy MK, Campbell PJ, Yu T, Hraber PT, Irene C, Pinter A, Chomba E, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E.

Retrovirology. 2012 Sep 20;9:76. doi: 10.1186/1742-4690-9-76.

35.

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.

Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, Zheng R, Gill K, Verma M, Yu T, Johnson B, Li B, Derdeyn CA, Ibegbu C, Altman JD, Hunter E, Feinberg MB.

J Virol. 2012 Dec;86(23):12605-15. doi: 10.1128/JVI.00246-12. Epub 2012 Sep 12.

36.

B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.

Boliar S, Murphy MK, Tran TC, Carnathan DG, Armstrong WS, Silvestri G, Derdeyn CA.

J Virol. 2012 Aug;86(15):8031-40. doi: 10.1128/JVI.00771-12. Epub 2012 May 23.

37.

A gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission Pairs.

Manigart O, Boeras DI, Karita E, Hawkins PA, Vwalika C, Makombe N, Mulenga J, Derdeyn CA, Allen S, Hunter E.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1745-55. doi: 10.1089/AID.2012.0023. Epub 2012 Jul 3.

38.

Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses.

Kraft CS, Basu D, Hawkins PA, Hraber PT, Chomba E, Mulenga J, Kilembe W, Khu NH, Derdeyn CA, Allen SA, Manigart O, Hunter E.

Retrovirology. 2012 Mar 20;9:22. doi: 10.1186/1742-4690-9-22.

39.

Cloning and analysis of sooty mangabey alternative coreceptors that support simian immunodeficiency virus SIVsmm entry independently of CCR5.

Elliott ST, Riddick NE, Francella N, Paiardini M, Vanderford TH, Li B, Apetrei C, Sodora DL, Derdeyn CA, Silvestri G, Collman RG.

J Virol. 2012 Jan;86(2):898-908. doi: 10.1128/JVI.06415-11. Epub 2011 Nov 16.

40.

Role of donor genital tract HIV-1 diversity in the transmission bottleneck.

Boeras DI, Hraber PT, Hurlston M, Evans-Strickfaden T, Bhattacharya T, Giorgi EE, Mulenga J, Karita E, Korber BT, Allen S, Hart CE, Derdeyn CA, Hunter E.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):E1156-63. doi: 10.1073/pnas.1103764108. Epub 2011 Nov 7.

41.

Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques.

Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B, Carnathan PM, Cramer EM, Engram JC, Little DM, Ryzhova E, Gonzalez-Scarano F, Paiardini M, Ansari AA, Ratcliffe S, Else JG, Brenchley JM, Collman RG, Estes JD, Derdeyn CA, Silvestri G.

J Clin Invest. 2011 Nov;121(11):4433-45. doi: 10.1172/JCI46023. Epub 2011 Oct 17.

42.

The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, Allen S, Robinson JE, Gnanakaran S, Derdeyn CA.

J Virol. 2011 Jan;85(2):905-15. doi: 10.1128/JVI.02006-10. Epub 2010 Oct 27.

43.

A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo.

Riddick NE, Hermann EA, Loftin LM, Elliott ST, Wey WC, Cervasi B, Taaffe J, Engram JC, Li B, Else JG, Li Y, Hahn BH, Derdeyn CA, Sodora DL, Apetrei C, Paiardini M, Silvestri G, Collman RG.

PLoS Pathog. 2010 Aug 26;6(8):e1001064. doi: 10.1371/journal.ppat.1001064.

44.

Measuring HIV fusion mediated by envelopes from primary viral isolates.

Cavrois M, Neidleman J, Galloway N, Derdeyn CA, Hunter E, Greene WC.

Methods. 2011 Jan;53(1):34-8. doi: 10.1016/j.ymeth.2010.05.010. Epub 2010 Jun 8.

45.

Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection.

Lynch RM, Rong R, Li B, Shen T, Honnen W, Mulenga J, Allen S, Pinter A, Gnanakaran S, Derdeyn CA.

Virology. 2010 Aug 15;404(1):59-70. doi: 10.1016/j.virol.2010.04.010. Epub 2010 May 21.

46.

Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies.

Li B, Stefano-Cole K, Kuhrt DM, Gordon SN, Else JG, Mulenga J, Allen S, Sodora DL, Silvestri G, Derdeyn CA.

J Virol. 2010 Jun;84(12):6248-53. doi: 10.1128/JVI.00295-10. Epub 2010 Apr 7.

47.

Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry.

Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E.

J Virol. 2010 Apr;84(8):4100-4. doi: 10.1128/JVI.02068-09. Epub 2010 Feb 10.

48.

Genetic and antigenic features of the transmitted virus.

Keele BF, Derdeyn CA.

Curr Opin HIV AIDS. 2009 Sep;4(5):352-7. doi: 10.1097/COH.0b013e32832d9fef. Review.

PMID:
20048697
49.

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA.

PLoS Pathog. 2009 Sep;5(9):e1000594. doi: 10.1371/journal.ppat.1000594. Epub 2009 Sep 18.

50.

Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization.

Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn CA, Collman RG.

J Virol. 2009 Aug;83(16):8208-20. doi: 10.1128/JVI.00296-09. Epub 2009 Jun 10.

Supplemental Content

Loading ...
Support Center